Renal Cell Carcinoma: Durable Responses and Long-Term Survival

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on the concept of durable responses and the potential long-term survival tail observed with first-line immunotherapy-based regimens in renal cell carcinoma. The panel explores how these outcomes are explained to patients in a clear and realistic manner, particularly when discussing expectations for long-term disease control. Dr. Ramalingam and Dr. Ged highlight that while not all patients experience sustained benefit, a subset may achieve prolonged responses that extend beyond traditional expectations seen with earlier therapies. The discussion also addresses how this potential for durable benefit influences treatment strategy, including the selection of immunotherapy-based combinations in appropriate patients. This segment underscores the importance of communicating both optimism and uncertainty when discussing long-term outcomes in renal cell carcinoma.